Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Axsome Therapeutics, Inc. has recently announced the initiation of the FOCUS Phase 3 trial for solriamfetol, a promising investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) in adults. The primary objective of this trial is to evaluate the efficacy and safety of solriamfetol in approximately 450 adult patients over a duration of 6 weeks. Solriamfetol belongs to the class..